Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: a single-center experience

Abstract Myeloperoxidase-type antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis may manifest various organ symptoms. Treatment allows recovery from early, but severe, organ involvement. However, the relationship between the initial organ involvement and the eventual clinical cours...

Full description

Saved in:
Bibliographic Details
Published inModern rheumatology Vol. 19; no. 4; pp. 420 - 426
Main Authors Nakabayashi, Kimimasa, Arimura, Yoshihiro, Yoshihara, Ken, Fukuoka, Toshihiro, Karube, Miho, Yamato, Tunee, Koji, Hitoshi, Ikegaya, Noriko, Ohtuka, Takako, Kawashima, Sohko, Sudo, Miyako, Yamada, Akira
Format Journal Article
LanguageEnglish
Published United States Informa Healthcare 01.08.2009
Taylor & Francis
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Myeloperoxidase-type antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis may manifest various organ symptoms. Treatment allows recovery from early, but severe, organ involvement. However, the relationship between the initial organ involvement and the eventual clinical course has not been studied in this disease. Therefore, the current study evaluated 30 patients who were hospitalized and then categorized into ten clinical subtypes based on organ involvement. The relationship of these subtypes to development of clinical features, patient survival, kidney prognosis, and relapse were evaluated over an average observation period of 4.3 years. During this study, the most common clinical features were lung and kidney involvement. Twenty-one patients already manifested clinical features around the time of admission and did not commonly present new symptoms as long as they were receiving the treatment for vasculitis. In contrast, as far as pulmonary involvement type at the initial time was concerned and in those not being treated for vasculitis, 7 of the 12 patients progressed to pulmo-renal involvement and 5 of them went onto renal failure. Progression to renal failure also occurred frequently in patients with pulmo-renal type manifesting at the initial time. Thirteen patients died, including three patients due to vasculitis of systemic type, seven due to infections, and three due to malignancy. Death due to vasculitis occurred in the early phase of treatment and was associated with either pulmonary hemorrhage or gastrointestinal bleeding. Infectious death occurred throughout the entire course of treatment, mostly in patients with pulmo-renal or pulmonary type, and tended to be associated with opportunistic organisms. Death with malignancy was observed after several years of treatment. Regarding renal prognosis, ten patients underwent hemodialysis. At initiation of hemodialysis, nine patients had pulmo-renal type and only one had renal type. A relapse was observed in ten patients, mainly in patients with pulmo-renal or pulmonary type, and it occurred after about 2.7 years, even with treatment. Such relapses manifested in a similar manner to their initial clinical subtypes. These results suggest that pulmo-renal type as well as pulmonary type have a high chance to progress to renal failure or systemic type, and they were fairly commonly associated with vasculitic or infectious death. Therefore, classification of clinical subtypes at the initial time and on admission is meaningful to some extent for predicting patient survival, kidney prognosis, and relapse, in addition to indicating the appropriate treatment regimen.
AbstractList Myeloperoxidase-type antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis may manifest various organ symptoms. Treatment allows recovery from early, but severe, organ involvement. However, the relationship between the initial organ involvement and the eventual clinical course has not been studied in this disease. Therefore, the current study evaluated 30 patients who were hospitalized and then categorized into ten clinical subtypes based on organ involvement. The relationship of these subtypes to development of clinical features, patient survival, kidney prognosis, and relapse were evaluated over an average observation period of 4.3 years. During this study, the most common clinical features were lung and kidney involvement. Twenty-one patients already manifested clinical features around the time of admission and did not commonly present new symptoms as long as they were receiving the treatment for vasculitis. In contrast, as far as pulmonary involvement type at the initial time was concerned and in those not being treated for vasculitis, 7 of the 12 patients progressed to pulmo-renal involvement and 5 of them went onto renal failure. Progression to renal failure also occurred frequently in patients with pulmo-renal type manifesting at the initial time. Thirteen patients died, including three patients due to vasculitis of systemic type, seven due to infections, and three due to malignancy. Death due to vasculitis occurred in the early phase of treatment and was associated with either pulmonary hemorrhage or gastrointestinal bleeding. Infectious death occurred throughout the entire course of treatment, mostly in patients with pulmo-renal or pulmonary type, and tended to be associated with opportunistic organisms. Death with malignancy was observed after several years of treatment. Regarding renal prognosis, ten patients underwent hemodialysis. At initiation of hemodialysis, nine patients had pulmo-renal type and only one had renal type. A relapse was observed in ten patients, mainly in patients with pulmo-renal or pulmonary type, and it occurred after about 2.7 years, even with treatment. Such relapses manifested in a similar manner to their initial clinical subtypes. These results suggest that pulmo-renal type as well as pulmonary type have a high chance to progress to renal failure or systemic type, and they were fairly commonly associated with vasculitic or infectious death. Therefore, classification of clinical subtypes at the initial time and on admission is meaningful to some extent for predicting patient survival, kidney prognosis, and relapse, in addition to indicating the appropriate treatment regimen.
Abstract Myeloperoxidase-type antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis may manifest various organ symptoms. Treatment allows recovery from early, but severe, organ involvement. However, the relationship between the initial organ involvement and the eventual clinical course has not been studied in this disease. Therefore, the current study evaluated 30 patients who were hospitalized and then categorized into ten clinical subtypes based on organ involvement. The relationship of these subtypes to development of clinical features, patient survival, kidney prognosis, and relapse were evaluated over an average observation period of 4.3 years. During this study, the most common clinical features were lung and kidney involvement. Twenty-one patients already manifested clinical features around the time of admission and did not commonly present new symptoms as long as they were receiving the treatment for vasculitis. In contrast, as far as pulmonary involvement type at the initial time was concerned and in those not being treated for vasculitis, 7 of the 12 patients progressed to pulmo-renal involvement and 5 of them went onto renal failure. Progression to renal failure also occurred frequently in patients with pulmo-renal type manifesting at the initial time. Thirteen patients died, including three patients due to vasculitis of systemic type, seven due to infections, and three due to malignancy. Death due to vasculitis occurred in the early phase of treatment and was associated with either pulmonary hemorrhage or gastrointestinal bleeding. Infectious death occurred throughout the entire course of treatment, mostly in patients with pulmo-renal or pulmonary type, and tended to be associated with opportunistic organisms. Death with malignancy was observed after several years of treatment. Regarding renal prognosis, ten patients underwent hemodialysis. At initiation of hemodialysis, nine patients had pulmo-renal type and only one had renal type. A relapse was observed in ten patients, mainly in patients with pulmo-renal or pulmonary type, and it occurred after about 2.7 years, even with treatment. Such relapses manifested in a similar manner to their initial clinical subtypes. These results suggest that pulmo-renal type as well as pulmonary type have a high chance to progress to renal failure or systemic type, and they were fairly commonly associated with vasculitic or infectious death. Therefore, classification of clinical subtypes at the initial time and on admission is meaningful to some extent for predicting patient survival, kidney prognosis, and relapse, in addition to indicating the appropriate treatment regimen.
Author Karube, Miho
Yamada, Akira
Sudo, Miyako
Fukuoka, Toshihiro
Arimura, Yoshihiro
Ikegaya, Noriko
Ohtuka, Takako
Koji, Hitoshi
Yamato, Tunee
Nakabayashi, Kimimasa
Yoshihara, Ken
Kawashima, Sohko
Author_xml – sequence: 1
  givenname: Kimimasa
  surname: Nakabayashi
  fullname: Nakabayashi, Kimimasa
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 2
  givenname: Yoshihiro
  surname: Arimura
  fullname: Arimura, Yoshihiro
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 3
  givenname: Ken
  surname: Yoshihara
  fullname: Yoshihara, Ken
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 4
  givenname: Toshihiro
  surname: Fukuoka
  fullname: Fukuoka, Toshihiro
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 5
  givenname: Miho
  surname: Karube
  fullname: Karube, Miho
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 6
  givenname: Tunee
  surname: Yamato
  fullname: Yamato, Tunee
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 7
  givenname: Hitoshi
  surname: Koji
  fullname: Koji, Hitoshi
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 8
  givenname: Noriko
  surname: Ikegaya
  fullname: Ikegaya, Noriko
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 9
  givenname: Takako
  surname: Ohtuka
  fullname: Ohtuka, Takako
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 10
  givenname: Sohko
  surname: Kawashima
  fullname: Kawashima, Sohko
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 11
  givenname: Miyako
  surname: Sudo
  fullname: Sudo, Miyako
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
– sequence: 12
  givenname: Akira
  surname: Yamada
  fullname: Yamada, Akira
  email: kiminaka@krd.biglobe.ne.jp, kiminaka@krd.biglobe.ne.jp
  organization: First Department of Internal Medicine, Kyorin University School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19521745$$D View this record in MEDLINE/PubMed
BookMark eNp9kMuOFCEUhokZ41z0AdwYHmBQKIqqQt10Ot6S0XGha3KaOkwz0lCB6h77bXxU6fRMjAvdcP2_H_Kdk5OYIhLyXPCXUnD9qgguOsU414yLoWH8ETkTrdSs77g-eVgrrU7JeSm3nEulB_2EnAqtGtG36oz8WgYoxTtvYfYp0uSoDT7WbaBlu5r3E5ZLOtVLjHM9yTu_g3BJf_gx4p5OOd3EVHzNQBxpxgBTQerjA1LonZ_X9PPXa7b4slyw-liyHmYc6Q6K3QY_-_KaAi0-3gRktjKYKf6cMFfe4lPy2EEo-Ox-viDf37_7tvzIrq4_fFourphteqGYBD52HW-V67Sw1inunBxQAApuR2xArriu49C1cuhl22O_Gm0nmq7vrOqVvCDi2GtzKiWjM1P2G8h7I7g52DZH26baNgfbhlfmxZGZtqsNjn-Ie7018PYY8NGlvIG7lMNoZtiHlF2GaH05dP-7_81f-BohzGsLGc1t2uZYffznd78BARmmbw
CitedBy_id crossref_primary_10_1007_s11926_009_0061_x
crossref_primary_10_1016_j_gie_2010_10_042
crossref_primary_10_1111_1756_185X_14929
crossref_primary_10_1016_j_autrev_2017_05_008
crossref_primary_10_1111_j_1440_1827_2010_02571_x
crossref_primary_10_3899_jrheum_170249
Cites_doi 10.1046/j.1523-1755.2002.00605.x
10.1681/ASN.V7133
ContentType Journal Article
Copyright 2009 Japan College of Rheumatology 2009
Copyright_xml – notice: 2009 Japan College of Rheumatology 2009
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.3109/s10165-009-0182-0
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1439-7609
EndPage 426
ExternalDocumentID 10_3109_s10165_009_0182_0
19521745
11288669
Genre Original Article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID ---
-5E
-5G
-BR
-Y2
.55
.86
00X
0R~
0VY
123
1N0
29M
2JY
2P1
2VQ
2~H
30V
36B
3V.
4.4
408
409
40D
53G
5VS
5WD
67Z
6NX
7X7
88E
8AO
8FI
8FJ
8G5
8TC
8UJ
95.
95~
AABZA
AACZT
AAIAL
AAJNR
AALUX
AANXM
AAPBV
AAPXW
AARHV
AAUGY
AAVAP
ABBKH
ABEIZ
ABMNI
ABPTD
ABPTK
ABTEG
ABUPF
ABUWG
ACENM
ACFUF
ACGFS
ACKZS
ACOMO
ADBBV
ADCVX
ADFCX
ADFZZ
ADINQ
ADIPN
ADKPE
ADQRH
ADRBQ
ADRFC
ADVEK
AECIN
AENEX
AEYQI
AFFZL
AFKRA
AFLOW
AGJBK
AGUTN
AHBYD
AHMBA
AHSBF
AIJEM
AIRBT
AJEEA
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AMKLP
ASPBG
AVWKF
AZFZN
AZQEC
BA0
BABNJ
BCRHZ
BENPR
BGNMA
BLEHA
BOHLJ
BPHCQ
BVXVI
CAG
CCCUG
COF
CS3
CSCUP
CZDIS
DKSSO
DL5
DRXRE
DU5
DWQXO
DWTOO
EBS
EJD
EMB
EMOBN
EN4
F5P
FEDTE
FYUFA
GNUQQ
GQ6
GUQSH
GXS
H13
HF~
HG5
HG6
HMJXF
HZ~
I09
IHE
IXC
IXE
IZIGR
IZQ
I~X
KBUDW
KDC
KOP
KPH
KRBQP
KSI
KSN
KSSTO
KWAYT
KYCEM
LAS
LJTGL
M1P
M2O
M4Y
M4Z
MA-
NB0
NOMLY
NU0
O9-
O93
O9I
OAM
OAUYM
OCZFY
OPAEJ
OVD
OWPYF
P2P
P9S
PADUT
PQEST
PQQKQ
PQUKI
PROAC
PSQYO
Q2X
QOS
R9I
RIG
RNS
ROL
ROX
RPX
RSV
S1Z
S27
S37
S3B
SDH
SMD
SOJ
SV3
SZN
T13
TEORI
TFDNU
TFL
TFW
TSK
TSV
TT1
TUC
U2A
UKHRP
V1S
VC2
WJK
WK8
X7M
Z45
Z7U
Z82
Z87
~A9
AARHZ
AAUAY
AAYZH
ABJNI
ABNHQ
ABPQP
ABQNK
ABXVV
ADQBN
AFBBN
AGYJP
ALIPV
ATGXG
BEYMZ
CCPQU
CGR
CUY
CVF
ECM
EIF
HMCUK
HVGLF
NPM
OJZSN
TDBHL
AAYXX
CITATION
ID FETCH-LOGICAL-c2715-3a0d66045f691ccf50ff38e1ae10cde2a3b092a3864387347e7bdc612676c5753
ISSN 1439-7595
IngestDate Fri Aug 23 01:22:06 EDT 2024
Tue Oct 15 23:36:14 EDT 2024
Tue Jul 04 18:14:58 EDT 2023
Tue Jul 04 19:19:31 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2715-3a0d66045f691ccf50ff38e1ae10cde2a3b092a3864387347e7bdc612676c5753
PMID 19521745
PageCount 7
ParticipantIDs informaworld_taylorfrancis_310_3109_s10165_009_0182_0
informahealthcare_journals_10_3109_s10165_009_0182_0
crossref_primary_10_3109_s10165_009_0182_0
pubmed_primary_19521745
PublicationCentury 2000
PublicationDate 2009-08-01
PublicationDateYYYYMMDD 2009-08-01
PublicationDate_xml – month: 08
  year: 2009
  text: 2009-08-01
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Modern rheumatology
PublicationTitleAlternate Mod Rheumatol
PublicationYear 2009
Publisher Informa Healthcare
Taylor & Francis
Publisher_xml – name: Informa Healthcare
– name: Taylor & Francis
References Jennette JC (CIT0001) 1994; 37
Kawamoto S (CIT0007) 1999; 41
Nachman PH (CIT0012) 1996; 7
Sakai H (CIT0014) 2002; 44
Hogan S (CIT0004) 1996; 7
Fujii A (CIT0015) 2000; 53
Hauer HA (CIT0008) 2002; 62
Nagakawa T (CIT0010) 1995; 18
Gordon M (CIT0011) 1993; 86
Falk RJ (CIT0002) 1990; 113
Bajema IM (CIT0006) 1999; 56
Westman KWA (CIT0005) 1998; 9
References_xml – volume: 18
  start-page: 127
  year: 1995
  ident: CIT0010
  publication-title: Lab Mach Reag
  contributor:
    fullname: Nagakawa T
– volume: 113
  start-page: 656
  year: 1990
  ident: CIT0002
  publication-title: Clinical course of antineutrophil cyto-plasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med
  contributor:
    fullname: Falk RJ
– volume: 62
  start-page: 1732
  year: 2002
  ident: CIT0008
  publication-title: Kidney Int
  doi: 10.1046/j.1523-1755.2002.00605.x
  contributor:
    fullname: Hauer HA
– volume: 7
  start-page: 23
  year: 1996
  ident: CIT0004
  publication-title: Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associ-ated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol
  contributor:
    fullname: Hogan S
– volume: 53
  start-page: 242
  year: 2000
  ident: CIT0015
  publication-title: Clin Nephrol
  contributor:
    fullname: Fujii A
– volume: 41
  start-page: 719
  year: 1999
  ident: CIT0007
  publication-title: Analysis of risk factor for patients and renal survival in anti-myeloperoxidase antibody (MPO-ANCA) associated glo-merulonephritis (in Japanese, abstract in English). Jpn J Nephrol
  contributor:
    fullname: Kawamoto S
– volume: 9
  start-page: 842
  year: 1998
  ident: CIT0005
  publication-title: Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol
  contributor:
    fullname: Westman KWA
– volume: 44
  start-page: 55
  year: 2002
  ident: CIT0014
  publication-title: The treatment guideline for rapidly progressive glomerulonephritis (in Japanese). Jpn J Nephrol
  contributor:
    fullname: Sakai H
– volume: 56
  start-page: 1751
  year: 1999
  ident: CIT0006
  publication-title: Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int
  contributor:
    fullname: Bajema IM
– volume: 86
  start-page: 779
  year: 1993
  ident: CIT0011
  publication-title: Q J Med
  contributor:
    fullname: Gordon M
– volume: 37
  start-page: 187
  year: 1994
  ident: CIT0001
  publication-title: Proposal of an inter-national consensus conference. Arthritis Rheum
  contributor:
    fullname: Jennette JC
– volume: 7
  start-page: 33
  year: 1996
  ident: CIT0012
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.V7133
  contributor:
    fullname: Nachman PH
SSID ssj0035989
Score 1.840233
Snippet Abstract Myeloperoxidase-type antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis may manifest various organ symptoms. Treatment allows...
Myeloperoxidase-type antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis may manifest various organ symptoms. Treatment allows recovery from...
SourceID crossref
pubmed
informaworld
informahealthcare
SourceType Aggregation Database
Index Database
Publisher
StartPage 420
SubjectTerms Aged
Aged, 80 and over
Antibodies, Antineutrophil Cytoplasmic - blood
Clinical subtype
Female
Humans
Japan - epidemiology
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - etiology
Kidney Failure, Chronic - pathology
Male
Middle Aged
MPO-ANCA
Peroxidase - blood
Prednisolone - therapeutic use
Prognosis
Relapse
Survival Rate
Vasculitis
Vasculitis - blood
Vasculitis - classification
Vasculitis - drug therapy
Vasculitis - mortality
Title Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: a single-center experience
URI https://www.tandfonline.com/doi/abs/10.3109/s10165-009-0182-0
https://www.ncbi.nlm.nih.gov/pubmed/19521745
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEuqDxbXtoDJ5otTrz22tyiiqoCJXBIpXCydu21YqWxqzhGgl_Dz-LnMPvwKykIellFm8xqpe_LeGY8D4TepDQOaOx7ZOQmDqE8lERQ8HmY6yZMBJKNfVU7PJ35F5f048JbDAa_OllL1Vacxj9urCu5DaqwB7iqKtn_QLY5FDbgM-ALKyAM6z9hrCdaqlyfxu5rCx0roaKrGiXbOxX2QC980x3-T1ZZkoM6UOlZeVGaRgM61Vxe8etSdxKxYrb-bfrlM5nMziaEW0DBUjVprKorkqmZVnGHK0lUwqfc2OEBsmZVPTbKDF_bLGUFxnIvqD_jKy74dzXeSeufbJ2teclbTmbrSo9FOvlawG-W2aZolZba4ObbT21523m1qoqV3p33ZOpAR9ik2RlqzvdmjnTUNphVhHlmXOep7Oz5TtjT9WGH07SjuOnY6dgA1FTx7z5eXNOdtdQ1YERfEdwz4rTP0ibDEczYIPD98A66OwYVqJIN2aIJBai2iaGue7P3Nu_b1fnv9k7vWUyHtp_usskO3Omxu-MeaTNpfogeWP8GTwxZH6KBzB-he1ObwfEY_exzFhcprjmLa84OsaUerhk7xIavuOHrEANbsWUrzvJapMSKrfgGtuKWre8xxz2u4parT9Dl-Yf52QWxU0JIPGYjj7jcSXwfPJPUD0dxnHpOmrqBHHE5cuJEjrkrnBDWAGzvgLmUSSaSGAx7n_kxOCvuU3SQF7k8QjgAcRG48NALHcqEJ5w4EAJcGhp4zPWSY_S2RiK6Ns1gInCiFWyRgS0C2CIFW-QcI7qHVWSVR_k3Ma8LZ7TVtE8N45XMH-WeGdzbm4Weijd4z2954gt0v_0bvkQH200lX4EFvhWvNZl_A2wx3uA
link.rule.ids 315,783,787,27938,27939
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Classification+of+clinical+subtypes%2C+patient+survival%2C+kidney+prognosis%2C+and+relapse+in+patients+with+MPO-ANCA-associated+vasculitis%3A+a+single-center+experience&rft.jtitle=Modern+rheumatology&rft.au=Nakabayashi%2C+Kimimasa&rft.au=Arimura%2C+Yoshihiro&rft.au=Yoshihara%2C+Ken&rft.au=Fukuoka%2C+Toshihiro&rft.date=2009-08-01&rft.pub=Taylor+%26+Francis&rft.issn=1439-7595&rft.eissn=1439-7609&rft.volume=19&rft.issue=4&rft.spage=420&rft.epage=426&rft_id=info:doi/10.3109%2Fs10165-009-0182-0&rft.externalDocID=11288669
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1439-7595&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1439-7595&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1439-7595&client=summon